She worked to retrain her right hand, and since 2009 has been performing again as a guitarist, singer, and songwriter. Berkley Breathed, American Pulitzer Prize winning comic strip artist and book writer/illustrator. Known for Bloom County,  Opus, and others. His work was featured as that of the main character, as an adult, of the film Second Hand Lions. Stuart Cassells, founder of the bagpipe rock group Red Hot Chilli Pipers, announced focal dystonia in September 2011; he has left the band. Andrew Dawes, noted violinist and co-founder of the Orford String Quartet. Warren Deck, former tubist of the New York Philharmonic. Keith Emerson, pianist and keyboard player
Leon Fleisher, an international concert pianist, dealt with this condition in his right hand beginning in the 1960s and switched to only left hand playing. In the 2000s, he regained use of his right hand and recommenced performing and recording with two hands. Dominic Frasca, guitarist
Reinhard Goebel, Baroque violinist, switched to playing left-handed. Gary Graffman, pianist, who changed to performing only with his left hand. Jang Jae-in, Korean singer-songwriter and guitarist diagnosed with dystonia in her left hand in 2012. In 2015, on You Hee-yeols Sketchbook, she announced that she quit playing guitar. Alex Klein, principal oboist of the Chicago Symphony Orchestra
Alfred Koffler, guitarist of rock band Pink Cream 69, diagnosed in early 2000s. To help him with live shows, Uwe Reitenauer was hired as a second guitarist. Koffler continues to write and perform live on stage with the band.
The pharmacological research of cisatracurium and the other individual isomers was then developed further primarily by R. Brandt Maehr and William B. Wastila, PhD (both of whom were pharmacologists within the Division of Pharmacology at Burroughs Wellcome Co.) in collaboration with John J. Savarese MD (who at the time was an anesthesiologist in the Dept. of Anesthesia, Harvard Medical School at the Massachusetts General Hospital, Boston, MA). Thereafter, the entire clinical development of cisatracurium was completed in a record short period from 1992 to 1994: the team of scientists was led by J. Neal Weakly PhD, Martha M. Abou-Donia PhD, and Steve Quessy PhD, in the Division of Clinical Neurosciences at Burroughs Wellcome Co., Research Triangle Park, NC. By the time of its approval for human use, in 1995, by the US Food and Drug Administration, Burroughs Wellcome Co. had merged with Glaxo Inc., and cisatracurium was approved to be marketed as Nimbex by GlaxoWellcome Inc. The trade name "Nimbex" was derived from inserting an "i" to the original proposal "Nmbex," which stood for excellent Neuromuscular blocker. Preclinical pharmacology
In vitro studies using human plasma indicated that cisatracurium spontaneously degrades at physiological pH via Hofmann elimination to yield laudanosine and the quaternary monoacrylate. Subsequent ester hydrolysis of the monoacrylate generates the monoquaternary alcohol, although the rate-limiting step is Hofmann elimination. In rat plasma, cisatracurium is also metabolized by non-specific carboxylesterases (a rate-limiting step) to the monoquaternary alcohol and the monoquaternary acid.